Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aldeyra Therapeu (ALDX)

Aldeyra Therapeu (ALDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 434,008
  • Shares Outstanding, K 38,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -60,830 K
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.24
Trade ALDX with:

Options Overview

Details
  • Implied Volatility 136.26%
  • Historical Volatility 86.65%
  • IV Percentile 49%
  • IV Rank 4.25%
  • IV High 1,400.54% on 03/19/20
  • IV Low 80.07% on 10/20/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 992
  • Volume Avg (30-Day) 954
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 10,004
  • Open Int (30-Day) 11,696

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.29
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +44.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.90 +7.68%
on 03/05/21
14.52 -26.58%
on 02/16/21
-1.58 (-12.91%)
since 02/08/21
3-Month
6.47 +64.76%
on 01/05/21
14.62 -27.08%
on 01/19/21
+3.40 (+46.83%)
since 12/08/20
52-Week
1.48 +620.27%
on 03/17/20
14.62 -27.08%
on 01/19/21
+7.14 (+202.84%)
since 03/06/20

Most Recent Stories

More News
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 11, 2021 to report financial results for the year ended December 31, 2020 and discuss recent...

ALDX : 10.66 (-4.65%)
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the H.C....

ALDX : 10.66 (-4.65%)
What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

PRGO : 41.82 (+1.90%)
ALDX : 10.66 (-4.65%)
PETQ : 34.39 (+2.53%)
ORGO : 15.03 (-0.40%)
Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare...

ALDX : 10.66 (-4.65%)
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?

On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.

EBS : 86.23 (-6.59%)
ALDX : 10.66 (-4.65%)
AUPH : 12.72 (-2.83%)
VXRT : 6.03 (+0.17%)
Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated...

ALDX : 10.66 (-4.65%)
Thinking about buying stock in Aemetis, Aldeyra Therapeutics, Seelos Therapeutics, INmune Bio, or O2Micro International?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMTX, ALDX, SEEL, INMB, and OIIM.

AMTX : 13.15 (+8.14%)
INMB : 13.12 (-8.32%)
OIIM : 6.69 (-4.84%)
SEEL : 2.83 (+8.85%)
ALDX : 10.66 (-4.65%)
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated...

ALDX : 10.66 (-4.65%)
Thinking about buying stock in Gevo, Applied DNA Sciences, Surface Oncology, Aldeyra Therapeutics, or BioNano Genomics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, APDN, SURF, ALDX, and BNGO.

BNGO : 7.77 (+8.67%)
SURF : 7.36 (-1.87%)
ALDX : 10.66 (-4.65%)
APDN : 7.82 (-1.39%)
GEVO : 7.29 (+4.44%)
Thinking about buying stock in DBV Technologies, Endra Life Sciences, Precision BioSciences, Sorrento Therapeutics, or Aldeyra Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DBVT, NDRA, DTIL, SRNE, and ALDX.

DBVT : 5.25 (+0.77%)
DTIL : 10.68 (-7.13%)
ALDX : 10.66 (-4.65%)
NDRA : 2.12 (-4.50%)
SRNE : 8.79 (-1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 11.91
2nd Resistance Point 11.65
1st Resistance Point 11.15
Last Price 10.66
1st Support Level 10.39
2nd Support Level 10.13
3rd Support Level 9.63

See More

52-Week High 14.62
Last Price 10.66
Fibonacci 61.8% 9.60
Fibonacci 50% 8.05
Fibonacci 38.2% 6.50
52-Week Low 1.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar